Case-finding strategies in non-alcoholic fatty liver disease
| العنوان: | Case-finding strategies in non-alcoholic fatty liver disease |
|---|---|
| المؤلفون: | Jérôme Boursier, Emmanuel Tsochatzis |
| المساهمون: | Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM) |
| المصدر: | JHEP Reports Innovation in Hepatology JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100219. ⟨10.1016/j.jhepr.2020.100219⟩ JHEP Reports |
| بيانات النشر: | Elsevier BV, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Cirrhosis, Cost effectiveness, [SDV]Life Sciences [q-bio], NICE, National Institute of Clinical Excellence, Nice, Review, AST, aspartate aminotransferase, Disease, Patient pathway, ELF, enhanced liver fibrosis, 0302 clinical medicine, Immunology and Allergy, Medicine, NFS, NAFLD fibrosis score, ALD, alcohol-related liver disease, ComputingMilieux_MISCELLANEOUS, computer.programming_language, 0303 health sciences, NAS, NAFLD activity score, Case-finding, Fatty liver, Gastroenterology, Awareness, Primary care, TE, transient elastography, 3. Good health, Screening, FIB-4, 030211 gastroenterology & hepatology, Elastography, NAFLD, non-alcoholic fatty liver disease, medicine.medical_specialty, NASH, non-alcoholic steatohepatitis, Liver fibrosis, QALY, quality-adjusted life year, 03 medical and health sciences, ALT, alanine aminotransferase, Type 2 diabetes mellitus, NIT, non-invasive test, Internal Medicine, GP, general practitioner, FIB-4, fibrosis-4, Intensive care medicine, 030304 developmental biology, Hepatology, business.industry, Type 2 Diabetes Mellitus, T2DM, type 2 diabetes mellitus, medicine.disease, Quality-adjusted life year, Cost-effectiveness, Transient elastography, business, computer |
| الوصف: | Summary Among the large population of patients with non-alcoholic fatty liver disease (NAFLD), identifying those with advanced disease remains challenging. Many patients are diagnosed late, following the development of liver-related complications, leading to poor clinical outcomes. Accumulating evidence suggests that using non-invasive tests for liver fibrosis in patients with metabolic risk factors improves the detection of patients in need of specialised management and is cost-effective. Because of the vast number of patients requiring evaluation, the active participation of general practitioners and physicians who manage patients with metabolic disorders, such as diabetologists, is crucial; this calls for the increased awareness of NAFLD beyond liver clinics. Non-invasive case-finding strategies will need to be further validated and generalised for upcoming drug therapies to have the required impact on the worldwide burden of NAFLD. |
| تدمد: | 2589-5559 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::998a5dc5ae8854bb83716af6e6873dc7Test https://doi.org/10.1016/j.jhepr.2020.100219Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....998a5dc5ae8854bb83716af6e6873dc7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 25895559 |
|---|